This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
2 Blue-Chip Tech Stocks to Buy Before Earnings and Hold
by Benjamin Rains
The episode breaks down Apple and Microsoft ahead of their upcoming financial results to see if investors might want to buy these giant tech stocks right now...
Home Building Data Disappoints
by Zacks Equity Research
Home Building Data Disappoints
Home Building Disappoints Last Month; J&J and P&G Beat on Earnings
by Mark Vickery
One of the most important components of the Great Reopening of the past 6+ months has been the housing market, though it has been anything but steady.
J&J (JNJ) Beats on Q3 Earnings, Misses on Sales, Ups EPS View
by Zacks Equity Research
J&J (JNJ) reports mixed third-quarter earnings. It beats estimates for earnings but misses the same for sales. It raises its earnings guidance range for the year.
Johnson & Johnson (JNJ) Q3 Earnings Beat Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 9.70% and -1.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Markets Bounce Back on S&P 500, Nasdaq
by Mark Vickery
We closed the first trading day of the week mixed, after starting the day in the red across the board.
Optimism Reenters The Market But Will It Last As Earnings Season Picks Up?
by Daniel Laboe
All the major averages have officially broken above their 50-day moving averages, a pivotal "risk-on" technical signal as we enter the heart of Q3 earnings season
Focus on Q3 Earnings Season: Global Week Ahead
by John Blank
Big banks got us off to a flying start in this Q3 earnings season. But we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week¿¿¿s reporting docket.
Big Earnings Reports on Cards this Week
by Zacks Equity Research
Big Earnings Reports on Cards this Week
J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization
by Zacks Equity Research
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
Profit-Taking to Start a New Trading Week
by Mark Vickery
After a strong trading week last week, the Dow is down -190 points, the S&P 500 is -25 and the Nasdaq -75 points.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
Netflix, Tesla, Snap, Johnson & Johnson and Procter & Gamble are part of Zacks Earnings Preview
by Zacks Equity Research
Netflix, Tesla, Snap, Johnson & Johnson and Procter & Gamble are part of Zacks Earnings Preview
Into the Heart of Q3 Earnings Season
by Sheraz Mian
The big banks got us off to a flying start in this Q3 earnings season, but we will get a true sense of how good or otherwise the corporate profitability picture is after seeing the coming week's reporting docket.
Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?
by Zacks Equity Research
Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.
Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $157.69, moving -1.6% from the previous trading session.
Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
J&J (JNJ) Seeks Stelara Label Expansion in Juvenile Arthritis
by Zacks Equity Research
J&J (JNJ) files a regulatory application, seeking the label expansion of its inflammatory drug, Stelara, as a potential treatment of juvenile psoriatic arthritis.
What Lies Ahead for Dow ETFs in Q3 Earnings?
by Sweta Killa
With some of the blue-chip companies expected to report an earnings surprise, investors should closely monitor the movement of the Dow ETF.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Should SPDR MSCI USA StrategicFactors ETF (QUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QUS
Moderna (MRNA) Gets EMA Authorization for SpikeVax Third Dose
by Zacks Equity Research
Moderna (MRNA) gets authorization for the third dose of its COVID-19 vaccine, Spikevax, for use in immunocompromised individuals in Europe.
J&J (JNJ) Seeks FDA Authorization for COVID-19 Booster Jab
by Zacks Equity Research
J&J (JNJ) submits data to the FDA to support an authorization for the booster dose of its single-shot COVID-19 vaccine.
Company News for Oct 6, 2021
by Zacks Equity Research
Companies in The News Are: PEP, JNJ, OCGN, SPWR.